ScreenerHero

KMDAKamada Ltd.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · kamada.com
8.240USDMkt Cap: 475.40M $P/E: 21.68

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pa…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap475.40M $
Enterprise Value347.49M $
Revenue (TTM)181.68M $
Gross Profit76.41M $
Net Income (TTM)20.20M $
Revenue/Share3.119 USD
Last Price8.240 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees462
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)21.68
P/E (Forward)13.44
PEG0.63
EV/EBITDA8.93
EV/Revenue1.91
P/S2.55
P/B1.78
EPS (TTM)0.38
EPS (Forward)0.60
52W Range
8.02096% of range8.250
52W High8.250 USD
52W Low8.020 USD
Profitability
Gross Margin42.34%
Oper. Margin15.37%
EBITDA Margin21.42%
Profit Margin11.19%
ROE7.51%
ROA5.33%
Growth
Revenue Growth2.80%
Earnings Growth0.00%
Cash Flow & Leverage
Operating CF25.49M $
CapEx (TTM)9.85M $
FCF Margin6.10%
FCF Yield2.33%
Net Debt-61.51M $
Net Debt/EBITDA-1.58
Balance Sheet
Debt/Equity0.04
Current Ratio3.33
Quick Ratio1.90
Book Value/Sh4.497 USD
Cash/Share1.268 USD
Dividends
Fwd Div Rate0.2500 USD
Trail. Div Rate0.0000 USD
Div. Yield3.53%
5Y Avg Yield—
Payout Ratio71.43%
Ex-Div DateMar 23, 2026
Pay DateApr 7, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.50 USD
Upside (mean)+63.8%
Target Range11.00 USD – 15.00 USD
$11.00+63.8% to mean$15.00
# Analysts4
Ownership
Shares Out.57.69M
Float31.27M
Insiders7.20%
Institutions47.89%
Short Interest
Short Ratio3.8d
Short % Float0.42%
Short % Out.0.23%
Shares Short131.14K
Short (prev mo.)153.34K
Technical
SMA 507.254 (+13.6%)
SMA 2007.742 (+6.4%)
Beta0.13
S&P 52W Chg21.00%
Avg Vol (30d)112.84K
Avg Vol (10d)194.96K
Technical Indicators
RSI (14)72.5
MACD0.2059
MACD Signal0.0857
MACD Hist.+0.1202
BB Upper8.144 USD
BB Middle7.361 USD
BB Lower6.577 USD
BB Width21.28%
ATR (14)0.2305 USD
Vol Ratio (20d)0.86x